References
  1. Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010 Aug;376(9741):631–44.
  2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. Br J Med. 2007 Nov;335(7627):974
  3. Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020 Oct;371:m3502.
  4. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013 Jan;28(1):1–19.
  5. Smith GN, Pudwell J, Walker M, Wen S-W. Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can. 2012 Sep;34(9):830–5.
  6. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008 Nov;156(5):918–30.
  7. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010 Jul;56(1):166–71.
  8. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005 Nov;366(9499):1797–803.
  9. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001 Jun;357(9273):2002–6.
  10. Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, et al. A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol. 2009 Jan;200(1):58.e1-8.
  11. Heidema WM, Scholten RR, Lotgering FK, Spaanderman MEA. History of preeclampsia is more predictive of cardiometabolic and cardiovascular risk factors than obesity. Eur J Obstet Gynecol Reprod Biol. 2015 Nov; 194:189–93.
  12. Yinon Y, Kingdom JCP, Odutayo A, Moineddin R, Drewlo S, Lai V, et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation. 2010 Nov;122(18):1846–53.
  13. Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension. 2011 Jul;58(1):63–9.
  14. Fillion A, Guerby P, Menzies D, Lachance C, Comeau M-P, Bussières M-C, et al. Pathological investigation of placentas in preeclampsia (the PEARL study). Hypertens Pregnancy. 2021 Feb;40(1):56–62.
  15. Weiner E, Feldstein O, Tamayev L, Grinstein E, Barber E, Bar J, et al. Placental histopathological lesions in correlation with neonatal outcome in preeclampsia with and without severe features. Pregnancy Hypertens. 2018 Apr;12:6–10.
  16. Kovo M, Schreiber L, Ben-Haroush A, Gold E, Golan A, Bar J. The placental component in early-onset and late-onset preeclampsia in relation to fetal growth restriction. Prenat Diagn. 2012 Jul;32(7):632–7.
  17. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019 Jul;366:l2381.
  18. Schneider H. Placental dysfunction as a key element in the pathogenesis of preeclampsia. Dev Period Med. 2017;21(4):309–16.
  19. Benton SJ, Leavey K, Grynspan D, Cox BJ, Bainbridge SA. The clinical heterogeneity of preeclampsia is related to both placental gene expression and placental histopathology. Am J Obstet Gynecol. 2018 Dec;219(6): 604.e1-604.e25.
  20. Falco ML, Sivanathan J, Laoreti A, Thilaganathan B, Khalil A. Placental histopathology associated with pre-eclampsia: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017 Sep;50(3):295–301.
  21. Catov JM, Muldoon MF, Reis SE, Ness RB, Nguyen LN, Yamal J-M, et al. Preterm birth with placental evidence of malperfusion is associated with cardiovascular risk factors after pregnancy: a prospective cohort study. BJOG. 2018 Jul;125(8):1009–17.
  22. Brosens I, Benagiano M, Puttemans P, D’Elios MM, Benagiano G. The placental bed vascular pathology revisited: a risk indicator for cardiovascular disease. J Matern Fetal Neonatal Med. 2019 May;32(9):1556–64.
  23. Stevens DU, Smits MP, Bulten J, Spaanderman MEA, van Vugt JMG, Al-Nasiry S. Prevalence of hypertensive disorders in women after preeclamptic pregnancy associated with decidual vasculopathy. Hypertens pregnancy. 2015;34(3):332–41.
  24. Stevens DU, Al-Nasiry S, Fajta MM, Bulten J, van Dijk AP, van der Vlugt MJ, et al. Cardiovascular and thrombogenic risk of decidual vasculopathy in preeclampsia. Am J Obstet Gynecol. 2014 Jun;210(6):545.e1-6.
  25. Veerbeek JHW, Smit JG, Koster MPH, Post Uiterweer ED, van Rijn BB, Koenen S V, et al. Maternal cardiovascular risk profile after placental abruption. Hypertension. 2013 Jun;61(6):1297–301.
  26. Parks WT, Catov JM. The placenta as a window to maternal vascular health. Obstet Gynecol Clin North Am. 2020 Mar;47(1):17–28.
  27. Park K, Minissian MB, Wei J, Saade GR, Smith GN. Contemporary clinical updates on the prevention of future cardiovascular disease in women who experience adverse pregnancy outcomes. Clin Cardiol. 2020 Jun;43(6):553–9.
  28. Cusimano MC, Pudwell J, Roddy M, Cho C-KJ, Smith GN. The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications. Am J Obstet Gynecol. 2014;210(5):438.e1-438.e9.
  29. Smith GN. The Maternal Health Clinic: Improving women’s cardiovascular health. Semin Perinatol. 2015 Jun;39(4):316–9.
  30. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014 May;36(5):416-41.
  31. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001 Aug;108(2):E35.
  32. Warrander LK, Batra G, Bernatavicius G, Greenwood SL, Dutton P, Jones RL, Sibley CP, Heazell AE. Maternal perception of reduced fetal movements is associated with altered placental structure and function. PLoS One. 2012;7(4):e34851.
  33. Benton SJ, Lafreniere AJ, Grynspan D, Bainbridge SA. A synoptic framework and future directions for placental pathology reporting. Placenta. 2019 Feb;77:46-57.
  34. Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PWF, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006 Feb;113(6):791–8.
  35. Holzman CB, Senagore P, Xu J, Dunietz GL, Strutz KL, Tian Y, et al. Maternal risk of hypertension 7-15 years after pregnancy: clues from the placenta. BJOG. 2021 Apr;128(5):827–36.
  36. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27(9–10):939–58.
  37. Bustamante Helfrich B, Chilukuri N, He H, Cerda SR, Hong X, Wang G, et al. Maternal vascular malperfusion of the placental bed associated with hypertensive disorders in the Boston Birth Cohort. Placenta. 2017 Apr; 52:106–13.
  38. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population-based cohort study. BMJ. 2007 Nov;335(7627):978.
  39. Pavan L, Tsatsaris V, Hermouet A, Therond P, Evain-Brion D, Fournier T. Oxidized low-density lipoproteins inhibit trophoblastic cell invasion. J Clin Endocrinol Metab. 2004 Apr;89(4):1969–72.
  40. Pavan L, Hermouet A, Tsatsaris V, Thérond P, Sawamura T, Evain-Brion D, et al. Lipids from oxidized low-density lipoprotein modulate human trophoblast invasion:  involvement of nuclear liver X receptors. Endocrinology. 2004 Oct;145(10):4583–91.
  41. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol. 2001 Nov;98(5 Pt 1):757–62.
  42. Bodnar LM, Ness RB, Harger GF, Roberts JM. Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol. 2005 Dec;162(12):1198–206.
  43. Otun HA, Lash GE, Innes BA, Bulmer JN, Naruse K, Hannon T, et al. Effect of tumour necrosis factor-α in combination with interferon-γ on first trimester extravillous trophoblast invasion. J Reprod Immunol. 2011 Jan;88(1):1–11.
  44. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension. 2004 Nov;44(5):708–14.
  45. Garrido-Gimenez C, Mendoza M, Cruz-Lemini M, Galian-Gay L, Sanchez-Garcia O, Granato C, et al. Angiogenic factors and long-term cardiovascular risk in women that developed preeclampsia during pregnancy. Hypertension. 2020 Dec;76(6):1808–16.
  46. Benschop L, Schalekamp-Timmermans S, Broere-Brown ZA, Roeters van Lennep JE, Jaddoe VW V, Roos-Hesselink JW, et al. Placental growth factor as an indicator of maternal cardiovascular risk after pregnancy. Circulation. 2019 Apr;139(14):1698–709.
  47. Akhter T, Wikström A-K, Larsson M, Larsson A, Wikström G, Naessen T. Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia. Ultrasound Obstet Gynecol. 2017 Jul;50(1):93–9.
  48. Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, Luksha L, Kublickiene K. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1381-7.
  49. Amraoui F, Spijkers L, Hassani Lahsinoui H, Vogt L, van der Post J, Peters S, Afink G, Ris-Stalpers C, van den Born BJ. SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice. PLoS One. 2014 Mar 14;9(3):e91897.
  50. Sills A, Steigman C, Ounpraseuth ST, Odibo I, Sandlin AT, Magann EF. Pathologic examination of the placenta: recommended versus observed practice in a university hospital. Int J Womens Health. 2013 Jun 12;5:309–12.
Table 1. Maternal characteristics of the study participants as a combined cohort and by individual study site. Presented as mean ± SD, median [IQR] or n (%).